Literature DB >> 22475958

How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.

Eli D Ehrenpreis1, Arthur A Ciociola, Prasad M Kulkarni.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22475958     DOI： 10.1038/ajg.2011.449

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  3 in total

1.  Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.

Authors:  Eric D Shah; Elliot S Coburn; Anil Nayyar; Kerry Jo Lee; Jenna L Koliani-Pace; Corey A Siegel
Journal:  Aliment Pharmacol Ther       Date:  2020-01-28       Impact factor: 8.171

2.  Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning.

Authors:  Nilay Kafali; Ana Progovac; Sherry Shu-Yeu Hou; Benjamin Lê Cook
Journal:  Psychiatr Serv       Date:  2017-12-15       Impact factor: 3.084

3.  End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.

Authors:  Shamia Hoque; Brian J Chen; Martin W Schoen; Kenneth R Carson; Jesse Keller; Bartlett J Witherspoon; Kevin B Knopf; Y Tony Yang; Benjamin Schooley; Chadi Nabhan; Oliver Sartor; Paul R Yarnold; Paul Ray; Laura Bobolts; William J Hrushesky; Michael Dickson; Charles L Bennett
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.